50 mcg salmeterol HFA MDI

DRUG2 trials

Sponsors

Boehringer Ingelheim

Conditions

Asthma

Phase 3

Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo and Salmeterol HydroFluoroAlkane (HFA) Metered Dose Inhaler (MDI) (50 mcg Twice Daily) in Patient With Moderate Persistent Asthma I

CompletedNCT01172808

Boehringer IngelheimAsthma

Start: 2010-08-31End: 2012-11-30Updated: 2014-06-09

Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo and Salmeterol HydroFluoroAlkane (HFA) Metered Dose Inhaler (MDI) (50 mcg Twice Daily) in Patient With Moderate Persistent Asthma II

CompletedNCT01172821

Boehringer IngelheimAsthma

Start: 2010-08-31End: 2012-11-30Updated: 2014-06-09

Related Papers

Tiotropium Respimat® add-on therapy to inhaled corticosteroids in patients with symptomatic asthma improves clinical outcomes regardless of baseline characteristics.

2019-09-3015 citations

Peak expiratory flow as an endpoint for clinical trials in asthma: a comparison with FEV<sub>1</sub>.

2019-07-1817 citations

Safety of tiotropium Respimat<sup>®</sup> in black or African-American patients with symptomatic asthma.

2019-07-022 citations

Add-on Tiotropium in Chinese Patients With Moderate Asthma: A Pooled Subgroup Analysis of MezzoTinA-Asthma 1 and 2.

2019-07-012 citations

Tiotropium Respimat Add-on Is Efficacious in Symptomatic Asthma, Independent of T2 Phenotype.

2017-11-2253 citations

P86 In vitro and clinical characterisation of the antistatic valved holding chamber aerochamber plus® flow-vu® for administrating tiotropium respimat® in 1–5-year-old children with persistent asthmatic symptoms

2017-11-15

Once-daily tiotropium Respimat add-on therapy improves lung function and asthma control in moderate symptomatic asthma, independent of baseline characteristics

2017-09-013 citations

P151 Tiotropium Respimat® add-on therapy reduces exacerbation risk in patients with moderate or severe symptomatic asthma, independent of TH2 status: Abstract P151 Table 1

Thorax2015-11-121 citations

P150 Once-daily tiotropium Respimat® reduces risk of severe asthma exacerbation and asthma worsening in symptomatic asthma, independent of allergic and inflammatory status

Thorax2015-11-12

Efficacy of tiotropium Respimat® in adults with moderate asthma, by baseline LTRA use

2015-09-011 citations

Long-Term Once-Daily Tiotropium Respimat® Is Well Tolerated and Maintains Efficacy over 52 Weeks in Patients with Symptomatic Asthma in Japan: A Randomised, Placebo-Controlled Study

PLoS ONE2015-04-2088 citations

Tiotropium or salmeterol as add-on therapy to inhaled corticosteroids for patients with moderate symptomatic asthma: two replicate, double-blind, placebo-controlled, parallel-group, active-comparator, randomised trials.

2015-02-12128 citations

Tiotropium respimat® add-on therapy reduces airflow obstruction in patients with symptomatic moderate asthma, independent of TH2 inflammatory status

Allergy Asthma and Clinical Immunology2014-12-01

P231 Once-daily Tiotropium Respimat(R): Safety And Tolerability Results From Five Phase Iii Trials In Adults With Symptomatic Asthma

Thorax2014-11-102 citations

S92 Efficacy Of Once-daily Tiotropium Respimat(R) 5 g From Five Phase Iii Trials In Adults With Symptomatic Asthma

Thorax2014-11-101 citations

Tiotropium as add-on therapy to inhaled corticosteroids for patients with symptomatic asthma: lung function and safety

Pneumologie2014-02-24

Tiotropium Respimat® in asthma: a double-blind, randomised, dose-ranging study in adult patients with moderate asthma

Respiratory Research2014-01-0177 citations